Oncotalks | Powered by Novartis

ESMO 2019 Marina Garassino, MD, PhD; Next immunotherapy strategies for lung cancer

ESMO , Lithuania , Albania
Share this item

Marina Garassino, MD, PhD from Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy is commenting on a session she chared: Special symposium: Next immunotherapy strategies for lung cancer

Related items

ESMO 2019 Valentina Guarneri, MD, PhD; Overall survival (OS) results of the Phase III MONALEESA-3 trial

ESMO 2019 Valentina Guarneri, MD, PhD; Overall survival (OS) results of the Phase III MONALEESA-3 trial

Valentina Guarneri, MD, PhD from the University of Padua, Padua, Italy is commenting on the abstract: LBA7_PR - Overall survival (OS) results of the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)

ESMO , Kisqali Channel , Latvia , Lithuania , Estonia , Hungary , Albania

00:03:29

ESMO 2019 Highlights on melanoma presented at ESMO 2019

ESMO 2019 Highlights on melanoma presented at ESMO 2019

Philippe Saiag, MD, PhD and Prof. Jean Jacques Grob, MD are sharing their personal hightlights on melanoma from ESMO 2019

ESMO , Latvia , Lithuania , Estonia , Hungary , Albania

00:02:10

ESMO 2019 Conleth Murphy, MD, PhD; Overall survival (OS) results of the Phase III MONALEESA-3 trial

ESMO 2019 Conleth Murphy, MD, PhD; Overall survival (OS) results of the Phase III MONALEESA-3 trial

Conleth Murphy, MD, PhD from the Bon Secours Cork Cancer Centre, Cork, Ireland is commenting on the abstract LBA7_PR - Overall survival (OS) results of the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)

ESMO , Kisqali Channel , Hungary , Lithuania , Albania

00:03:01

ESMO 2019- Highlights on breast cancer presented at ESMO 2019

ESMO 2019- Highlights on breast cancer presented at ESMO 2019

Conleth Murphy, MD, PhD and Ivan Bilic, MD, PhD sharing their personal highlights on breast cancer presented at ESMO 2019 in Barcelona

ESMO , Latvia , Lithuania , Estonia , Albania

00:02:21

ESMO 2019 prof. Sherko Kümmel, MD; LBA7_PR - Overall survival (OS) results of the Phase III MONALEESA-3 trial

ESMO 2019 prof. Sherko Kümmel, MD; LBA7_PR - Overall survival (OS) results of the Phase III MONALEESA-3 trial

prof. Sherko Kümmel, MD from the Kliniken Essen-Mitte, Essen, Germany is commenting on the abstract LBA7_PR - Overall survival (OS) results of the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)

ESMO , Hungary , Lithuania , Albania , Slovenia

00:02:45

ESMO 2019 Rachel Giles, PhD; Diagnosis, management, and burden of renal cell carcinomas

ESMO 2019 Rachel Giles, PhD; Diagnosis, management, and burden of renal cell carcinomas

Rachel Giles, PhD from Medicom Medical Publishers, Utrecht, The Netherlands is commenting on the abstract: 915PD - Diagnosis, management, and burden of renal cell carcinomas: Results from a global patient survey in 43 countries

ESMO , Hungary , Lithuania , Albania

00:05:16